A cross-sectional study of the association between heat shock protein 27 antibody titers, pro-oxidant-antioxidant balance and metabolic syndrome in patients with angiographically-defined coronary artery disease

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1390-1395

  Sahebkar, Amirhossein ^a,b   Pourghadamyari, Hossein ^a,b   Moohebati, Mohsen ^a,b   Parizadeh, Seyed Mohammad Reza ^b   Falsoleiman, Homa ^a,b   Dehghani, Mashallah ^a,b   Fazlinezhad, Afsoon ^a,b   Akhlaghi, Saeed ^b   Tavallaie, Shima ^a,b   Paydar, Roghayeh ^a,b   Ghayour Mobarhan, Majid ^a,b   Ferns, Gordon A ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KEELE UNIVERSITY   (United Kingdom)

Author keywords

Antibodies; Coronary artery disease; Heat shock protein 27; Metabolic syndrome X; Oxidative stress

Indexed keywords

ANTIOXIDANT; C REACTIVE PROTEIN; GLUCOSE; HEAT SHOCK PROTEIN 27; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PRIORITY JOURNAL; PROOXIDANT ANTIOXIDANT BALANCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

AGED; ANTIOXIDANTS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDANTS;

EID: 81555205709     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.011     Document Type: Article

References (48)

1. Campbell C.Y., Nasir K., Blumenthal R.S. Metabolic syndrome, subclinical coronary atherosclerosis, and cardiovascular risk. Am Heart Hosp J 2005, 3:105-110.
2. Shaw L.J., Berman D.S., Hendel R.C., Alazraki N., Krawczynska E., Borges-Neto S., et al. Cardiovascular disease risk stratification with stress single-photon emission computed tomography technetium-99m tetrofosmin imaging in patients with the metabolic syndrome and diabetes mellitus. Am J Cardiol 2006, 97:1538-1544.
3. Ford E.S., Giles W.H., Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004, 27:2444-2449.
4. Azizi F., Salehi P., Etemadi A., Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003, 61:29-37.
5. Hightower L.E. Heat shock, stress proteins, chaperones and proteotoxicity. Cell 1991, 66:191-197.
6. Welch W.J. How cells respond to stress. Sci Am 1993, 268:56-64.
7. Gupta M., Vavasis C., Frishman W.H. Heat shock proteins in cardiovascular disease: a new therapeutic target. Cardiol Rev 2004, 12:26-30.
8. Pockley A.G. Heat shock proteins, inflammation, and cardiovascular disease. Circulation 2002, 105:1012-1017.
9. Ghayour-Mobarhan M., Rahsepar A.A., Tavallaie S., Rahsepar S., Ferns G.A.A. Chapter 2 the potential role of heat shock proteins in cardiovascular disease. Evidence from in vitro and in vivo studies. Adv Clin Chem 2009, 48:27-72.
10. Liao D.F., Jin Z.G., Baas A.S., Daum G., Gygi S.P., Aebersold R., et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000, 275:189-196.
11. Lu X.Y., Chen L., Cai X.L., Yang H.T. Overexpression of heat shock protein 27 protects against ischaemia/reperfusion-induced cardiac dysfunction via stabilization of troponin I and T. Cardiovasc Res 2008, 79:500-508.
12. Shams S., Shafi S., Bodman-Smith K., Williams P., Mehta S., Ferns G.A. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: Association with established cardiovascular risk factors. Clin Chim Acta 2008, 395:42-46.
13. Ghayour-Mobarhan M., Sahebkar A., Parizadeh S.M., Moohebati M., Tavallaie S., Rezakazemi-Bajestani S.M., et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. Int J Exp Pathol 2008, 89:209-215.
14. Pourghadamyari H., Moohebati M., Parizadeh S.M., Falsoleiman H., Dehghani M., Fazlinezhad A., et al. Serum antibody titers against heat shock protein 27 are associated with the severity of coronary artery disease. Cell Stress Chaperones 2011, 16:309-316.
15. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438. American Heart Association; National Heart, Lung, and Blood Institute.
16. Alamdari D.H., Ghayour-Mobarhan M., Tavallaie S., Parizadeh M.R., Moohebati M., Ghafoori F., et al. Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 2008, 41:375-380.
17. Mehlen P., Preville X., Chareyron P., Briolay J., Klemenz R., Arrigo A.P. Constitutive expression of human Hsp27, Drosophila Hsp27, or human alpha B-crystallin confers resistance to TNF and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol 1995, 154:363-374.
18. Chen Y., Ross B.M., Currie R.W. Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta. Cell Stress Chaperones 2004, 9:99-107.
19. Mullen E., Ohlendieck K. Proteomic profiling of non-obese type 2 diabetic skeletal muscle. Int J Mol Med 2010, 25:445-458.
20. Martin-Ventura J.L., Duran M.C., Blanco-Colio L.M., Meilhac O., Leclercq A., Michel J.B., et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004, 110:2216-2219.
21. Robinson A.A., Dunn M.J., McCormack A., dos Remedios C., Rose M.L. Protective effect of phosphorylated Hsp27 in coronary arteries through actin stabilization. J Mol Cell Cardiol 2010, 49:370-379.
22. Kardys I., Rifai N., Meilhac O., Michel J.B., Martín-Ventura J.L., Buring J.E., et al. Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. Clin Chem 2008, 54:139-146.
23. Ciocca D.R., Oesterreich S., Chamness G.C., McGuire W.L., Fuqua S.A. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 1993, 85:1558-1570.
24. Porter W., Wang F., Wang W., Duan R., Safe S. Role of estrogen receptor/Sp1 complexes in estrogen induced heat shock protein 27 gene expression. Mol Endocrinol 1996, 10:1371-1378.
25. Huittinen T., Leinonen M., Tenkanen L., Mänttäri M., Virkkunen H., Pitkänen T., et al. Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk. Arterioscler Thromb Vasc Biol 2002, 22:431-437.
26. Zhu J., Quyyumi A.A., Rott D., Csako G., Wu H., Halcox J., et al. Antibodies to human heat shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune components of atherogenesis. Circulation 2001, 103:1071-1075.
27. Hoppichler F., Lechleitner M., Traweger C., Schett G., Dzien A., Sturm W., et al. Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis 1996, 126:333-338.
28. Wright B.H., Corton J., El-Nahas A.M., Wood R.F., Pockley A.G. Elevated levels of circulating heat shock protein 70 (Hsp70) in peripheral and renal vascular disease. Heart Vessels 2000, 15:18-22.
29. Wysocki J., Karawajczyk B., Górski J., Korzeniowski A., Maćkiewicz Z., Kupryszewski G., et al. Human heat shock protein 60 (409-424) fragment is recognized by serum antibodies of patients with acute coronary syndromes. Cardiovasc Pathol 2002, 11:238-243.
30. Xu Q., Willeit J., Marosi M., Kleindienst R., Oberhollenzer F., Kiechl S., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993, 341:255-259.
31. Frostegård J., Lemne C., Andersson B., Van Der Zee R., Kiessling R., De Faire U. Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 1997, 29:40-44.
32. Veres A., Füst G., Smieja M., McQueen M., Horváth A., Yi Q., et al. Relationship of anti-60kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation 2002, 106:2775-2780.
33. Xu Q., Kiechl S., Mayr M., Metzler B., Egger G., Oberhollenzer F., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999, 100:1169-1174.
34. Burt D., Bruno G., Chaturvedi N., Schalkwijk C., Stehouwer C.D., Witte D.R., et al. Anti-heat shock protein 27 antibody levels and diabetes complications in the EURODIAB study. Diabetes Care 2009, 32:1269-1271.
35. Ghayour-Mobarhan M., Lamb D.J., Lovell D.P., Livingstone C., Wang T., Ferns G.A.A. Plasma antibody titres to heat shock proteins-60, -65 and -70: their relationship to coronary risk factors in dyslipidaemic patients and healthy individuals. Scand J Clin Lab Invest 2005, 65:601-613.
36. Pengiran Burut D.F., Borai A., Livingstone C., Ferns G. Serum heat shock protein 27 antigen and antibody levels appear to be related to the macrovascular complications associated with insulin resistance: a pilot study. Cell Stress Chaperones 2010, 15:379-386.
37. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006, 41:1031-1040.
38. Alamdari D.H., Paletas K., Pegiou T., Sarigianni M., Befani C., Koliakos G. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 2007, 40:248-254.
39. Koliakos G.G., Befani C.D., Mikropoulos D., Ziakas N.G., Konstas A.G. Prooxidant-antioxidant balance, peroxide and catalase activity in the aqueous humour and serum of patients with exfoliation syndrome or exfoliative glaucoma. Graefes Arch Clin Exp Ophthalmol 2008, 246:1477-1483.
40. Parizadeh S.M.R., Azarpazhooh M.R., Mobarra N., Nemati M., Alamdari D.H., Tavallaie S., et al. Prooxidant-antioxidant balance in stroke patients and 6-month prognosis. Clin Lab 2011, 57:183-191.
41. Ghayour-Mobarhan M., Alamdari D.H., Moohebati M., Sahebkar A., Nematy M., Safarian M., et al. Determination of prooxidant-antioxidant balance after acute coronary syndrome using a rapid assay: a pilot study. Angiology 2009, 60:657-662.
42. Falsoleiman H., Dehghani M., Moohebati M., Fazlinezhad A., Daloee M.H., Alamdari D.H., et al. Changes in pro-oxidant-antioxidant balance after bare metal and drug eluting stent implantation in patients with stable coronary disease. Clin Biochem 2011, 44:160-164.
43. Parizadeh S.M.R., Azarpazhooh M.R., Moohebati M., Nematy M., Ghayour-Mobarhan M., Tavallaie S., et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 2011, 46:333-340.
44. Choi S.W., Benzie I.F., Ma S.W., Strain J.J., Hannigan B.M. Acute hyperglycemia and oxidative stress: direct cause and effect?. Free Radic Biol Med 2008, 44:1217-1231.
45. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006, 212:167-178.
46. Briones A.M., Touyz R.M. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 2010, 12:135-142.
47. Tabet F., Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin Sci 2009, 116:87-98.
48. Chen J., Mehta J.L. Role of oxidative stress in coronary heart disease. Indian Heart J 2004, 56:163-173.